Skip to content

Effects of folic acid intervention on the patients of Alzheimer's disease by DNA methylation

Effects of folic acid intervention on the patients of Alzheimer's disease by DNA methylation

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003246
Enrollment
Unknown
Registered
2013-05-04
Start date
2013-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease (AD)

Interventions

AD intervention group:folic acid, 1.25mg/day, oral, six months
control:without folic acid

Sponsors

Tianjin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Patients meet a probable Alzheimers disease of NIA-AA diagnostic criteria in 2011 who were diagnosed by 2 neurology physician; 2. All were examined detailed history, neurologic examination, neuropsychological test, PET, MRI and the necessary laboratory examination; 3. All were native Chinese, right-handed, sane and cooperative; 4. Aged from 40 to 90 years old.

Exclusion criteria

Exclusion criteria: 1. Neurological examination found the sign of local central nerve obstruction such as obvious paralysisunilateral sensory disturbance and aphasia etc, history of cerebrovascular diseases (hemorrhagic and ischemic stroke), brain injury or bone fracture; 2. Medical diseases such as asthmatic bronchitis, severe hypertension, angina pectoris and severe infection; 3. Psychotic patients with evident anxiety and depressed emotion and subjects with endocrine system history of disease(hyperthyroidism, thyroid hypofunction, systemic lupus eythematosus, rheumatoid arthritis); 4. Newly discovered or advanced tumor; 5. Visual perception, auditory perceptual disorders or languages communication difficulties, all of which may influence measurement of cognitive function; 6. Alcohol dependence and other psychoactive substance abuse such as antipsychotic drug,benzodiazepines or taking medicine influencing cognitive function.

Design outcomes

Primary

MeasureTime frame
Blood gene expression related;serum folate, plasma homocysteine, S-adenosyl homocysteine;MMSE scores, ADL scale;

Countries

China

Contacts

Public ContactGuowei Huang
huangguowei@tmu.edu.cn+86-22-83336606

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 2, 2026